



Reliance, Virtual Inspections and Regulations – Brazilian strategies during Covid -19 Pandemic

MsC Ihata Anderson Silva



Topics

Introduction

Regulation

Working Flow

Results

Perspectives



Introduction

National Surveillance System

- **Federal:** Anvisa (regulation, inspection, lab analysis, registration, post marketing, cGMP)
- **Local:** VISA (inspection, marketing license)



[Esta Foto](#) de Autor Desconhecido está licenciado em [CC BY-SA](#)



ANVISA

Agência Nacional de Vigilância Sanitária



Introduction

Intervention Technologies

- Regulation / legislation
- Post- Marketing Surveillance
- **Inspection**
- Monitoring
- Fiscal Analysis
- Adverse Event
- Epidemiologic Researches
- Information, communication and education



Introduction

Inspection

- Systematic observation
- Technical and scientific oriented
- Sanitary condition examination for premises, processes, products and transports
- International/National standards
- cGMP request vs routine basis



Regulation

RDC nº 301/2019

GMP requirements/guides

- Quality System, Periodic Quality Review, Top Management, Quality Indicator and Goals, Quality Manual, Quality Management, Attribution and Responsibilities
- Continuous Process Validation - QdD
- Quality Risk Management
- No retrospective validation allowed
- Reprocessing rejected products
- Efficacy evaluation after change control
- Process Analytical Technology (nondestructive analysis in lab)



Regulation

Resolution RDC nº 336, 30/jan/2020

Time to response in cGMP requirements

- 365 days to issue cGMP
- Non inspected or already inspected sites
- cGMP valid for 2 years



Regulation

Resolution RDC nº 346, 12/mar/20

GMP Certification

- Extraordinary and Temporary Procedures and Criteria for cGMP
- GMP requests
- External information vs Anvisa reports (Reliance?)



Regulation

Resolution RDC nº 346, 12/mar/2020

GMP Certification – Alternative Inspection Tools

- Remote Inspection (virtual/desk)
- Replace on-site inspection
- Video streaming
- Document evaluation
- Online tour on facilities



ANVISA

Agência Nacional de Vigilância Sanitária



Regulation

Resolution RDC nº 346, 12/mar/2020

GMP Certification – “One Way Reliance”

- Pharmaceuticals and API: PIC/S
- Medical Devices: MDSAP
- API and Excipients: ECA Academy -
Program to rationalize GMP inspection
for API



ANVISA

Agência Nacional de Vigilância Sanitária



Regulation

Resolution RDC nº 497, 20/may/2021

GMP Certification – Documentation 1st cGMP

- Anvisa and VISA inspection reports
- Audit Organization – Recognized
- Equivalent Regulatory Authorities (RA)



Regulation

Resolution RDC nº 497, 20/may/2021

GMP Certification – Documentation for further cGMP

- GMP compliance history
- Technical complaints,
- Quality deviations or
- Sanitary infringements/violations
- Confidential information from RA



Regulation

Resolution RDC nº 497, 20/may/2021

GMP Certification – Automatic cGMP Renewal

- 270 to 180 days before cGMP expiration
- cGMP published even if the inspection is not performed yet.



Work Flow

cGMP Request Evaluation

- **Manufacturer** - Inspection History
- **Products and Process** — criticality and complexity
- **Post Marketing** — quality complaint and recall
- **PIC/S** — Already inspected by PIC/S RA
- **Reliance** – Mutual Recognition (Switzerland, Argentina, Uruguay, etc.)



Working flow

cGMP Request Evaluation

GMP
inspection

Information
Request

cGMP
issuance

cGMP
rejection



ANVISA

Agência Nacional de Vigilância Sanitária



Working flow

Inspection Report for cGMP – During Pandemic

1st – Remote
Inspection

2nd – PIC/S,
MDSAP or
ECA

3rd – On site
or RDC 336
(cGMP without
inspection)



ANVISA

Agência Nacional de Vigilância Sanitária



Working flow

Remote inspections during pandemic

National – 1st
choice

International
– 1st choice

Investigation
– 2nd choice



Working flow

Remote inspections steps

E-mail notification (optional)

- Manufacturers are informed about remote inspection and requested to confirm (not mandatory)

Preliminary meeting

- Virtual evaluations for video streaming and sharing documentation systems
- Agenda details (date, days, time zones, time for synchronic interactions)

Remote Inspection



Working flow

Remote Inspections Agenda

GMP topic

- All GMP elements, or selected ones (history basis)

Synchronic Interactions


- Virtual tours on manufacturing (running), warehouse and labs
- Document, information and discussion

Document evaluation – desk documentation review



Working flow

Remote Inspections – Time zones





Working flow

Remote Inspections outcomes

Positive conclusion

- cGMP issuance

Negative conclusion

- cGMP Rejection
- Marketing Restrictions

On-site Inspections



Results

Inspection numbers

2019 – 223 on site inspections (none remote inspection)

- 102 domestic (64 pharmaceutical – 38 IFAs)
- 121 international (85 pharmaceuticals – 36 IFAs)

2020 – 79 on site inspections (8 hybrid inspections)

- 39 domestic (5 hybrid) – 28 pharmaceutical and 11 API
- 40 international (2 hybrid) – 35 pharmaceutical and 5 API

2021 – 58 on site inspections (15 remote/hybrid inspections)

- Planed and Performed



Results

Certification numbers

2020 - publications (per manufacturing lines)

- 1.417 cGMP for pharmaceuticals and biologics – 539 domestic
- 180 cGMP for API – 25 domestic

2021 – publications (per manufacturing lines)

- 967 cGMP for pharmaceuticals and biologics – 296 domestic
- 161 cGMP – 15 domestic



Perspectives

Remote inspections

- **Temporary and Extraordinary** – during the Pandemic
- **Low risk facilities** – case by case (depending on budget and personnel availabilities)
- **Hybrid models** – Must thing about.
- **Report Review** – No need for special evaluation (remote inspection replaces onsite inspection in every term)



Perspectives

Reliance

- One way reliance – during the Pandemic
- PIC/S members – case by case after initial contact
- Mercosul, Switzerland, Cuba – Still working .
- Regulations – Guides are in discussion



Perspectives

Domestic Inspections

- **Onsite inspection** — working using safety protocols
- **Hybrid inspection**— Anvisa's team by desk, Visa's team by onsite inspection



Perspectives

International Inspections

- **Onsite inspection** — only for vaccines, Covid-19 supporting treatment and specific cases (complaint, risk of drug shortages)
- **Remote Inspection** — Anvisa tem by desk, Visa team by onsite inspection



Obrigado. Thanks.

Gimed/GGFIS/Anvisa-Brasil
gimed@anvisa.gov.br